Our first recurring guest on our Spotlight Series is that of Chris Naprawa, whom is now the Chairman of Khiron Life Sciences (TSXV: KHRN), a Colombia-based international medical cannabis and CBD operator. After being featured on the first ever edition of the Spotlight Series, Chris has returned to discuss the international milestones as well as the latest developments of the firm.
Within, Naprawa addresses the recent milestone of achieving 1,000 medical patients within Colombia, and what that ultimately means for the balance sheet and income statement of the company. He then goes on discuss with us his take on the international markets, the significance of recent developments made by the company, and the firms outlook on international opportunities as they relate to North America and the rest of the world.
Finally, we address the current state of the cannabis market – the sector rotations we’ve seen as of late, as well as the impact that this rotation has on the fundamentals of cannabis firms at large. Watch the video below to get the full details of these discussions and more.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.